Skip to main content

Table 2 Changes of urinary deoxypyridinoline excretion during denosumab treatment

From: Two years’ experience with denosumab for children with Osteogenesis imperfecta type VI

  Urinary deoxypyridinoline/creatinine ratio (age related normal range)
Patient 1 Patient 2 Patient 3 Patient 4
Days after injection 1 st Cycle 1 st Cycle 1 st Cycle 1 st Cycle
Day 1 44 (6.5-26.5 nM/mM) 32 (6.5-26.5 nM/mM) 82 (6.5-26.5 nM/mM) 41 (0.0-17.8 nM/mM)
Day 14 14 (6.5-26.5 nM/mM) 25 (6.5-26.5 nM/mM) 26 (6.5-26.5 nM/mM) 20 (0.0-17.8 nM/mM)
Day 28 25 (6.5-26.5 nM/mM) 13 (6.5-26.5 nM/mM) 25 (6.5-26.5 nM/mM) 17 (0.0-17.8 nM/mM)
  3 rd Cycle 4 th Cycle 8 th Cycle 8 th Cycle
Day 1 48 (6.5-26.5 nM/mM) 78 (6.5-26.5 nM/mM) 620 (110–450 μg/g) 83 (10–50 μg/g)
Day 14 10 (6.5-26.5 nM/mM) 24 (6.5-26.5 nM/mM) 133 (110–450 μg/g) 50 (10–50 μg/g)
Day 28 32 (6.5-26.5 nM/mM) 19 (6.5-26.5 nM/mM) 431* (110–450 μg/g) 23 (10–50 μg/g)
  7 th Cycle 10 th Cycle - -
Day 1 42 (6.5-26.5 nM/mM) 477 (110–450 μg/g) - -
Day 14 28 (6.5-26.5 nM/mM) 110 (110–450 μg/g) - -
Day 28 19 (6.5-26.5 nM/mM) 197 (110–450 μg/g) - -
  1. Changes of urinary deoxypyridinoline levels (urinary deoxypyridinoline/creatinine ratio) presented exemplarily for different treatment cycles in all patients. Based on a change of the method reference ranges differed over the period and for clarity every reference range (as provided by the laboratories) are shown after every measured DPD level. The results of the first cycle and of previous bisphosphonate therapy have already been described in part [12].
  2. *→ Value 3 days after elective surgery of right femur due to dislocation of intramedullary rod.